Literature DB >> 3081918

Effect of a short-term oral administration of cimetidine and ranitidine on the basal and thyrotropin-releasing hormone-stimulated serum concentrations of prolactin, thyrotropin and thyroid hormones in healthy volunteers. A double-blind cross-over study.

G Perret, J N Hugues, M Louchahi, O Varoquaux, E Modigliani.   

Abstract

Cimetidine (400 mg b.d.), ranitidine (150 mg b.d.) and placebo were administered for 1 week to 6 healthy male volunteers in a randomized double-blind cross-over fashion. Hormonal concentrations before and after a TRH test were assessed before and after each treatment. A spontaneous decrease in the hormonal response to TRH was observed after placebo treatment. Both cimetidine and ranitidine induced a significant increase in basal prolactin (PRL) values. Neither TSH nor T3 were modified by cimetidine or by ranitidine. The basal concentration of reverse T3 was increased during cimetidine treatment. There was a significant rise in post-TRH T4 after cimetidine and ranitidine administration. These results suggest a role for histamine H2 receptors in the secretion of PRL and T4. Moreover, cimetidine affects the hepatic metabolism of thyroid hormones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081918     DOI: 10.1159/000138157

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  5 in total

1.  Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A).

Authors:  M Colle; E Ruedas; J Cazenave; J Auzerie; G Basilisco; G Camboni; L Manara
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Plasma concentrations of pituitary and peripheral hormones during ranitidine treatment for two years in men with duodenal ulcer.

Authors:  U Knigge; B Thuesen; A Dejgaard; P Bennett; P M Christiansen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 4.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.